Literature DB >> 34099864

Mapping genetic variability in mature miRNAs and miRNA binding sites in prostate cancer.

Bongyong Lee1,2, Jian-Liang Li3, John Marchica2, Mark Mercola4, Vipul Patel5, Ranjan J Perera6,7.   

Abstract

MicroRNAs (miRNAs) regulate diverse cancer hallmarks through sequence-specific regulation of gene expression, so genetic variability in their seed sequences or target sites could be responsible for cancer initiation or progression. While several efforts have been made to predict the locations of single nucleotide variants (SNVs) at miRNA target sites and associate them with cancer risk and susceptibility, there have been few direct assessments of SNVs in both mature miRNAs and their target sites to assess their impact on miRNA function in cancers. Using genome-wide target capture of miRNAs and miRNA-binding sites followed by deep sequencing in prostate cancer cell lines, here we identified prostate cancer-specific SNVs in mature miRNAs and their target binding sites. SNV rs9860655 in the mature sequence of miR-570 was not present in benign prostate hyperplasia (BPH) tissue or cell lines but was detectable in clinical prostate cancer tissue samples and adjacent normal tissue. SLC45A3 (prostein), a putative oncogene target of miR-1178, was highly upregulated in PC3 cells harboring an miR-1178 seed sequence SNV. Finally, systematic assessment of losses and gains of miRNA targets through 3'UTR SNVs revealed SNV-associated changes in target oncogene and tumor suppressor gene expression that might be associated with prostate carcinogenesis. Further work is required to systematically assess the functional effects of miRNA SNVs.
© 2021. The Author(s), under exclusive licence to The Japan Society of Human Genetics.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34099864     DOI: 10.1038/s10038-021-00934-w

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  49 in total

1.  The need for personalized therapy and companion diagnostics in prostate cancer.

Authors:  Richard J Ablin
Journal:  Biomark Med       Date:  2011-06       Impact factor: 2.851

Review 2.  MicroRNAs in cancer.

Authors:  Gianpiero Di Leva; Michela Garofalo; Carlo M Croce
Journal:  Annu Rev Pathol       Date:  2013-09-25       Impact factor: 23.472

3.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

4.  A comprehensive analysis of precursor microRNA cleavage by human Dicer.

Authors:  Yong Feng; Xiaoxiao Zhang; Paul Graves; Yan Zeng
Journal:  RNA       Date:  2012-09-14       Impact factor: 4.942

5.  Regulation of pre-miRNA Processing.

Authors:  Nicolas J Lehrbach; Eric A Miska
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

6.  Involvement of microRNA families in cancer.

Authors:  Stefan Wuchty; Dolores Arjona; Serdar Bozdag; Peter O Bauer
Journal:  Nucleic Acids Res       Date:  2012-06-28       Impact factor: 16.971

7.  The need for a personalized approach for prostate cancer management.

Authors:  J P Michiel Sedelaar; Jack A Schalken
Journal:  BMC Med       Date:  2015-05-09       Impact factor: 8.775

8.  MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance.

Authors:  Richard Ottman; Camha Nguyen; Robert Lorch; Ratna Chakrabarti
Journal:  Mol Cancer       Date:  2014-01-03       Impact factor: 27.401

Review 9.  Prostate cancer biomarkers: Are we hitting the mark?

Authors:  Shannon McGrath; Daniel Christidis; Marlon Perera; Sung Kyu Hong; Todd Manning; Ian Vela; Nathan Lawrentschuk
Journal:  Prostate Int       Date:  2016-07-29

10.  A novel role for GSK3β as a modulator of Drosha microprocessor activity and MicroRNA biogenesis.

Authors:  Claire E Fletcher; Jack D Godfrey; Akifumi Shibakawa; Martin Bushell; Charlotte L Bevan
Journal:  Nucleic Acids Res       Date:  2017-03-17       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.